Core C provides molecular assays for identifying, tracking, and quantifying cellular clones within complex multi-clonal mixtures. This function is designed to support basic stem cell biology, stem cell transplantation, and gene therapy research within the CCEH research base, but also among a broader community of basic and clinical scientists, at the FHCRC, UW, and other institutions. Services provided include VNTR analysis (Variable Number Tandem Repeat), to track the level of donor contribution in a transplant setting and LAM-PCR (Linear Amplification-Mediated PCR) to identify and track specific clones of cells in a chimeric mixture. Techniques are in place to estimate the level of gene transfer into stem cells, to estimate the number of stem cells engrafting, to detect the recruitment and exhaustion of individual stem cell clones, to identify leukemic outgrowth, and to determine insertion site specificity of retroviral vectors. A third assay category. Allele Tracking, has been added more recently to assist in the validation of transgenic and knockout mice developed by our users. To this end, we have developed nine multiplex PCR assays to quickly track the genotypes of several conditional knockout lines. Additional assays are developed a needed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK056465-14
Application #
8566004
Study Section
Special Emphasis Panel (ZDK1-GRB-G (O3))
Project Start
1999-09-15
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
14
Fiscal Year
2012
Total Cost
$147,405
Indirect Cost
$61,976
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Sorror, Mohamed L; Gooley, Ted A; Maclean, Kirsteen H et al. (2018) Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. Bone Marrow Transplant :
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Gust, Juliane; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7:1404-1419
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020

Showing the most recent 10 out of 267 publications